Biocon Biologics Global to raise funds through senior secured notes
The Notes shall not be offered or sold in India
The Notes shall not be offered or sold in India
Multi-year collaboration focuses on development of biodegradable antimicrobial peptides with broad application possibilities in the areas of skin care and healthcare
The company is making its mark through strategic initiatives, promising to become a significant presence in the evolving pharmaceutical sector
India Business grew by 11.9% YoY to Rs. 1196.2 crore
This strong performance was primarily on account of a one-time gain from the strategic collaboration between Biocon Biologics and Eris Lifesciences.
Sun Pharmaceutical Industries has reported total income of Rs. 13,185.30 crores during the period ended June 30, 2024
Boehringer Ingelheim aims to develop this program as a potential key centerpiece component for its immuno-oncology portfolio
Acquisition strengthens and diversifies Merck’s pipeline with the addition of Restoret
Acquisition to expand Lilly's immunology pipeline with oral integrin therapies
Subscribe To Our Newsletter & Stay Updated